Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data From KYSA-8 Trial of Miv-cel in Stiff Person Syndrome Transcript

Core Viewpoint - Kyverna Therapeutics is discussing top line data from the KYSA-8 registrational trial of mivocabtagene autoleucel (miv-cel) for patients with stiff person syndrome (SPS) [2] Group 1 - The conference call includes remarks from key executives such as the CEO and Chief Medical and Development Officer [4] - Investors are encouraged to visit the Investor Relations section of the company's website for press releases and presentation materials [3]